It's more than a result.
It's a person.

We're Driven To Know.


Innovative solutions that empower researchers, from ALS to fragile X syndrome.

Learn more about our Genetics portfolio

Solving complex molecular challenges, from leukemia to solid tumors.

Learn more about our Oncology portfolio
Custom & Companion Diagnostics

One partner from clinical concept to product commercialization.

Learn more about partnering with us.

Asuragen to Present at Upcoming Piper Jaffray Healthcare Conference

Asuragen President and Chief Executive Officer, Matthew McManus M.D., Ph.D., will present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 10:50 a.m. Eastern Time in New York.

Learn more

Asuragen Expands Portfolio into Alzheimer’s & Cognitive Impairment Space

Asuragen launches AmplideX® PCR/CE TOMM40 RUO Kit to advance studies of neurodegeneration, dementia progression and Alzheimer’s disease.

Read more

Asuragen Expands QuantideX® qPCR BCR-ABL Portfolio

Expansion of the CE-marked BCR-ABL Portfolio offers high quality, ultra-sensitive Major & minor fusion detection for monitoring CML patients.

Learn more

The Latest from Asuragen

Introducing the first and only FDA cleared BCR-ABL1 assay

We are pleased to announce that we have received FDA clearance through the de novo 510(k) process for our QuantideX qPCR BCR-ABL IS Kit for monitoring molecular response in Chronic Myeloid Leukemia patients.

Back To

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.